283 related articles for article (PubMed ID: 25089198)
1. Oncogene withdrawal engages the immune system to induce sustained cancer regression.
Casey SC; Li Y; Fan AC; Felsher DW
J Immunother Cancer; 2014; 2():24. PubMed ID: 25089198
[TBL] [Abstract][Full Text] [Related]
2. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.
Casey SC; Li Y; Felsher DW
Immunol Res; 2014 May; 58(2-3):282-91. PubMed ID: 24791942
[TBL] [Abstract][Full Text] [Related]
3. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
Bellovin DI; Das B; Felsher DW
Adv Exp Med Biol; 2013; 734():91-107. PubMed ID: 23143977
[TBL] [Abstract][Full Text] [Related]
4. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.
Felsher DW
Genes Cancer; 2010 Jun; 1(6):597-604. PubMed ID: 21037952
[TBL] [Abstract][Full Text] [Related]
5. Noncanonical roles of the immune system in eliciting oncogene addiction.
Casey SC; Bellovin DI; Felsher DW
Curr Opin Immunol; 2013 Apr; 25(2):246-58. PubMed ID: 23571026
[TBL] [Abstract][Full Text] [Related]
6. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.
Rakhra K; Bachireddy P; Zabuawala T; Zeiser R; Xu L; Kopelman A; Fan AC; Yang Q; Braunstein L; Crosby E; Ryeom S; Felsher DW
Cancer Cell; 2010 Nov; 18(5):485-98. PubMed ID: 21035406
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of MYC reverses tumorigenesis.
Li Y; Casey SC; Felsher DW
J Intern Med; 2014 Jul; 276(1):52-60. PubMed ID: 24645771
[TBL] [Abstract][Full Text] [Related]
8. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.
Bachireddy P; Rakhra K; Felsher DW
Clin Exp Immunol; 2012 Feb; 167(2):188-94. PubMed ID: 22235994
[TBL] [Abstract][Full Text] [Related]
9. MYC activation is a hallmark of cancer initiation and maintenance.
Gabay M; Li Y; Felsher DW
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
[TBL] [Abstract][Full Text] [Related]
10. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
Felsher DW
Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
[TBL] [Abstract][Full Text] [Related]
11. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.
Yetil A; Anchang B; Gouw AM; Adam SJ; Zabuawala T; Parameswaran R; van Riggelen J; Plevritis S; Felsher DW
Oncotarget; 2015 Feb; 6(6):3563-77. PubMed ID: 25784651
[TBL] [Abstract][Full Text] [Related]
12. MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC.
Dhanasekaran R; Park J; Yevtodiyenko A; Bellovin DI; Adam SJ; Kd AR; Gabay M; Fernando H; Arzeno J; Arjunan V; Gryanzov S; Felsher DW
Mol Ther Nucleic Acids; 2020 Sep; 21():850-859. PubMed ID: 32805488
[TBL] [Abstract][Full Text] [Related]
13. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegué E; Tang F; Folkman J; Felsher DW
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16266-71. PubMed ID: 17056717
[TBL] [Abstract][Full Text] [Related]
14. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.
Wu CH; van Riggelen J; Yetil A; Fan AC; Bachireddy P; Felsher DW
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13028-33. PubMed ID: 17664422
[TBL] [Abstract][Full Text] [Related]
15. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Choi PS; van Riggelen J; Gentles AJ; Bachireddy P; Rakhra K; Adam SJ; Plevritis SK; Felsher DW
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17432-7. PubMed ID: 21969595
[TBL] [Abstract][Full Text] [Related]
16. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.
Choi PS; Li Y; Felsher DW
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):E3316-24. PubMed ID: 25071175
[TBL] [Abstract][Full Text] [Related]
17. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.
Li Y; Deutzmann A; Choi PS; Fan AC; Felsher DW
Oncotarget; 2016 May; 7(19):26926-34. PubMed ID: 27095570
[TBL] [Abstract][Full Text] [Related]
18. Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Tran PT; Bendapudi PK; Lin HJ; Choi P; Koh S; Chen J; Horng G; Hughes NP; Schwartz LH; Miller VA; Kawashima T; Kitamura T; Paik D; Felsher DW
Sci Transl Med; 2011 Oct; 3(103):103ra99. PubMed ID: 21974937
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth.
Nwabugwu C; Rakhra K; Felsher D; Paik D
Comput Math Methods Med; 2013; 2013():802512. PubMed ID: 23573174
[TBL] [Abstract][Full Text] [Related]
20. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
Karlsson A; Giuriato S; Tang F; Fung-Weier J; Levan G; Felsher DW
Blood; 2003 Apr; 101(7):2797-803. PubMed ID: 12517816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
